imatinib mesylate has been researched along with Hematoma, Subdural in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barst, RJ; Bourge, RC; Feldman, J; Frost, AE; Galié, N; Ghofrani, HA; Gómez-Sánchez, MA; Grimminger, F; Grünig, E; Hassoun, PM; Hoeper, MM; Lawrence, D; Morrell, NW; Peacock, AJ; Quinn, DA; Satoh, T; Simonneau, G; Tapson, VF; Torres, F | 1 |
| Breitenstein, A; Domenighetti, G; Fischler, M; Huber, LC; Speich, R; Treder, U; Ulrich, S | 1 |
| Daniels, CE; Gabor, E; Lasky, JA; Limper, AH; Mieras, K; Schroeder, DR | 1 |
| Baer, MR; Gojo, I; Patel, SB; Sausville, EA; Tidwell, ML | 1 |
| Bassan, R | 1 |
| Al-Beirouti, B; Keating, A; Lipton, JH; McCrae, J; Messner, HA; Rifkind, J; Song, KW; Yee, K | 1 |
2 trial(s) available for imatinib mesylate and Hematoma, Subdural
| Article | Year |
|---|---|
Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.
Topics: Adolescent; Adult; Aged; Benzamides; Double-Blind Method; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hematoma, Subdural; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2013 |
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.
Topics: Aged; Anemia; Benzamides; Disease Progression; Double-Blind Method; Dyspnea; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematoma, Subdural; Humans; Idiopathic Pulmonary Fibrosis; Imatinib Mesylate; Leukopenia; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Respiratory Function Tests; Survival Analysis; Treatment Outcome | 2010 |
4 other study(ies) available for imatinib mesylate and Hematoma, Subdural
| Article | Year |
|---|---|
Efficacy and Safety of Long-Term Imatinib Therapy for Pulmonary Arterial Hypertension.
Topics: Adult; Aged; Echocardiography; Female; Hematoma, Subdural; Hemodynamics; Humans; Hypertension, Pulmonary; Imatinib Mesylate; International Normalized Ratio; Longitudinal Studies; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Remission Induction; Severity of Illness Index; Treatment Outcome; Young Adult | 2015 |
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fatal Outcome; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Injections, Spinal; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Treatment Outcome | 2011 |
Optimal central nervous system prophylaxis in Philadelphia chromosome-positive acute lymphoblastic leukemia: collateral damage in the imatinib era?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2011 |
Subdural hematomas during CML therapy with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Risk Factors; Thrombocytopenia; Treatment Outcome | 2004 |